Company: SHPH
Filing Date: 2025-02-26
Form Type: 10-K
Source: 0001493152-25-008300
Chunk: 235

Company: Shuttle Pharmaceuticals Holdings, Inc.
Filing Date: 2025-02-26
Form: 10-K
Item: Item 1A
Chunk 235
---
 If federal spending is reduced, anticipated budgetary shortfalls
may also impact the ability of relevant agencies, such as the FDA or the NIH to continue to function at current levels. Amounts
allocated to federal grants and contracts may be reduced or eliminated. These reductions may also impact the ability of relevant
agencies to timely review and approve drug research and development, manufacturing, and marketing activities, which may delay our
ability to develop, market and sell any products we may develop.

41

If
any of our product candidates receives marketing approval and we or others later identify undesirable side effects caused by the product
candidate, our ability to market and derive revenue from the product candidates could be compromised.

In
the event that any of our product candidates receive regulatory approval and we or others identify undesirable side effects caused by
one of our products, any of the following adverse events could occur, which could result in the loss of significant revenue to us and
materially and adversely affect our results of operations and business:

    ●
    regulatory
    authorities may withdraw their approval of the product or seize the product;

    ●
    we
    may be required to recall the product or change the way the product is administered to patients;

    ●
    additional
    restrictions may be imposed on the marketing of the particular product or the manufacturing processes for the product or any component
    thereof;

    ●
    we
    may be subject to fines, injunctions or the imposition of civil or criminal penalties;

    ●
    regulatory
    authorities may require the addition of labeling statements, such as a “black box” warning or a contraindication;

    ●
    we
    may be required to create a Medication Guide outlining the risks of such side effects for distribution to patients;

    ●
    we
    could be sued and held liable for harm caused to patients;

    ●
    the
    product may become less competitive; and

    ●
    our
    reputation.

Risks
Related to our Common Stock

If
we fail to comply with the continued listing requirements of The Nasdaq Stock Market, it could result in our common stock being delisted,
which could adversely affect the market price and liquidity of our securities and could have other adverse effects.

On
December 31, 2024, the Company received a letter from Nasdaq stating that for the 30 consecutive business day period between November
15, 2024 to December 30, 2024 the Company’s common stock